FEMOSTON-CONTI 0.5/2.5 Milligram Film Coated Tablet
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Patient Information leaflet
(PIL)
19-04-2024
Summary of Product characteristics
(SPC)
19-04-2024
Active ingredient:
ESTRADIOL DYDROGESTERONE
Available from:
Abbott Healthcare Products Ltd
INN (International Name):
ESTRADIOL DYDROGESTERONE
Dosage:
0.5/2.5 Milligram
Pharmaceutical form:
Film Coated Tablet
Prescription type:
Product subject to prescription which may not be renewed (A)
Authorization status:
Authorised
Authorization date:
0000-00-00
Patient Information leaflet
1
PACKAGE LEAFLET: INFORMATION FOR THE USER
FEMOSTON-CONTI
®
0.5 MG /2.5 MG, FILM-COATED TABLETS
Active substances: estradiol/dydrogesterone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE
YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Keep this leaflet. You may need to read it again.
If you have any further questions,
ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do
not pass it on to others. It may harm
them, even if their signs of illness are the same as yours.
If any of the side effects gets serious, or if you notice
any If you get any side effects, talk
to
your doctor or pharmacist. This includes any possible side effects not
listed in this
leaflet.
The full name of your medicine is Femoston-conti
®
0.5 mg/2.5 mg. In this leaflet the shorter
name Femoston is used.
WHAT IS IN THIS LEAFLET:
1. What Femoston is and what it is used for
2. What you need to know before you take Femoston
3. How to take Femoston
4. Possible side effects
5. How to store Femoston
6. Contents of the pack and other information
1.
WHAT FEMOSTON IS AND WHAT IT IS USED FOR
Femoston is a Hormone Replacement Therapy (HRT).
It contains two
types of female hormones, an oestrogen called estradiol and a
progestogen called
dydrogesterone. Femoston
is used in postmenopausal women with at least
12 months since their
last natural period.
-
FEMOSTON IS USED FOR
RELIEF OF SYMPTOMS OCCURRING AFTER MENOPAUSE
During the menopause, the amount of the oestrogen produced
by a woman’s body drops. This
can cause symptoms such as hot face, neck and
chest ("hot flushes"). Femoston alleviates these
2
symptoms
Read the complete document
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Femoston-conti 0.5mg/2.5mg film-coated tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
28 tablets, each containing 0.5 mg 17 -estradiol (as hemihydrate) and 2.5 mg dydrogesterone.
Excipient(s) with known effect: lactose monohydrate 117.4mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet.
A round, biconvex marked 379 on one side (7mm).
Yellow 0.5/2.5 mg tablets
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Hormone replacement therapy (HRT) for oestrogen deficiency symptoms in postmenopausal women at least 12 months
since last menses.
The experience in treating women older than 65 years is limited.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Femoston-conti 0.5 mg/2.5mg is a continuous combined HRT for oral use.
The oestrogen and the progestogen are given every day without interruption.
The dosage is one tablet per day for a 28 day cycle.
Femoston-conti 0.5mg/2.5mg should be taken continuously without a break between packs.
For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest
duration (see also section 4.4) should be used.
Continuous combined treatment may be started with Femoston-conti
®
0.5 mg/2.5 mg depending on the time since
menopause and severity of symptoms. Women experiencing a natural menopause should commence treatment with
Femoston-conti
®
0.5 mg/2.5 mg not earlier than at least 12 months after their last natural menstrual bleed. For
surgically induced menopause, treatment may start immediately.
Depending on the clinical response, the dosage can subsequently be adjusted.
Patients changing from a continuous sequential or cyclical preparation should complete the 28 day cycle and then
change to Femoston-
Read the complete document
